Wells Fargo
IMMX icon

Wells Fargo’s Immix Biopharma IMMX Stock Holding History

Wells Fargo’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
113,320
+96,171
+561% +$892K ﹤0.01% 3993
2026
Q1 		$156K Buy
+17,149
New +$126K ﹤0.01% 4847
2025
Q4 		– Sell
-330
Closed -$690 – 7232
2025
Q3 		$690 Hold
330
– – ﹤0.01% 6280
2025
Q2 		$683 Hold
330
– – ﹤0.01% 6346
2025
Q1 		$554 Hold
330
– – ﹤0.01% 6265
2024
Q4 		$726 Hold
330
– – ﹤0.01% 6287
2024
Q3 		$492 Hold
330
– – ﹤0.01% 6173
2024
Q2 		$653 Sell
330
-104
-24% -$239 ﹤0.01% 6123
2024
Q1 		$1.33K Buy
434
+43
+11% +$167 ﹤0.01% 6091
2023
Q4 		$2.71K Buy
391
+334
+586% +$1.51K ﹤0.01% 6048
2023
Q3 		$195 Buy
57
+15
+36% +$35 ﹤0.01% 6595
2023
Q2 		$113 Buy
42
+4
+11% +$8 ﹤0.01% 6840
2023
Q1 		$69 Buy
38
+1
+3% +$2 ﹤0.01% 7024
2022
Q4 		$85 Buy
37
+1
+3% +$1 ﹤0.01% 6836
2022
Q3 		$0 Sell
36
-34
-49% -$74 ﹤0.01% 6965
2022
Q2 		$0 Buy
70
+44
+169% +$86 ﹤0.01% 7111
2022
Q1 		$0 Buy
+26
New +$97 ﹤0.01% 7404

Other funds holding IMMX

JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo's IMMX Position: Q2 2026 in Review

Wells Fargo increased its Immix Biopharma (IMMX) stake by 561% in Q2 2026, buying an estimated $892K and bringing the position to 113,320 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #3993.

Wells Fargo first reported a position in IMMX in Q1 2022 and has held it in 17 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Wells Fargo held 113,320 shares of Immix Biopharma worth $1.17M as of Q2 2026.
  • Wells Fargo bought 96,171 Immix Biopharma shares in Q2 2026, an estimated $892K.
  • Immix Biopharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3993 holding.
  • Wells Fargo first reported a position in Immix Biopharma in Q1 2022 and has held it in 17 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.